Dipyridamole
As of the edition of 20 October 2026, Dipyridamole is a small molecule: marketed, first approved in 1986 (ES); acts on SLC29A1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1988
- Kind
- Small molecule
- Brand name
- Persantine
- First approved
- 1 April 1986 (ES)
- Approvals on record
- 7 in 3 regions
- Holder of the most recent approval
- Boehringer Ingelheim; 3 holders in all
- Registered trials
- 45, 7 stopped early
- Disease areas
- Heart and blood vessels; Nervous system; Immune system; Urinary and reproductive; Pregnancy and women's health; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| SLC29A1 | Equilibrative nucleoside transporter 1 | Q99808 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 6 | 3 | 0 | 1 |
| Phase 1 | 5 | 4 | 0 | 0 |
| Phase 2 | 17 | 7 | 2 | 4 |
| Phase 3 | 6 | 4 | 1 | 1 |
| Phase 4 | 11 | 9 | 0 | 1 |
| All trials | 45 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Boehringer Ingelheim | Applicant and Lead sponsor of trials | 1986 to now |